(Q46333189)

21 December 2017

title

Dual PDE 3/4 inhibition: a novel approach to airway disease? (English)

1 reference

21 December 2017

author name string

Jadwiga A Wedzicha

series ordinal

1

1 reference

21 December 2017

publication date

25 October 2013

1 reference

21 December 2017

The Lancet. Respiratory medicine

published in

1 reference

21 December 2017

volume

1

1 reference

21 December 2017

issue

9

1 reference

21 December 2017

page(s)

669-670

1 reference

21 December 2017

Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970211-X

7 January 2021

The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970211-X

7 January 2021

Effect of selective phosphodiesterase 3 inhibition on the early and late asthmatic responses to inhaled allergen

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970211-X

7 January 2021

Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970211-X

7 January 2021

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970211-X

7 January 2021

Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970211-X

7 January 2021

Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970211-X

7 January 2021

Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970211-X

7 January 2021

Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970211-X

7 January 2021

10.1016/S2213-2600(13)70211-X

Identifiers

DOI

1 reference

21 December 2017

1 reference

21 December 2017